var data={"title":"Tigecycline: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tigecycline: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/43923?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tigecycline-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tigecycline: Patient drug information&quot;</a> and <a href=\"topic.htm?path=tigecycline-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Tigecycline: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22813605\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Mortality: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">An increase in all-cause mortality has been observed in a meta-analysis of phase 3 and 4 clinical trials in tigecycline-treated patients versus comparator. The cause of this mortality risk difference of 0.6% (95% confidence interval [CI], 0.1 to 1.2) has not been established. Tigecycline should be reserved for use in situations when alternative treatments are not suitable.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786537\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Tygacil</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9749224\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Tygacil</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786540\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Glycylcycline</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786577\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">\n      <b>Pneumonia, community-acquired:</b> IV: Initial: 100 mg as a single dose; Maintenance dose: 50 mg every 12 hours for 7 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">\n      <b>Intra-abdominal infections, complicated (cIAI):</b> IV: Initial: 100 mg as a single dose; Maintenance dose: 50 mg every 12 hours for 5 to 14 days; <b>Note:</b> 2010 IDSA guidelines recommend a treatment duration of 4 to 7 days (provided source controlled) for community-acquired, mild-to-moderate IAI</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">\n      <b>Skin/skin structure infections, complicated:</b> IV: Initial: 100 mg as a single dose; Maintenance dose: 50 mg every 12 hours for 5 to 14 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22813606\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=tigecycline-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Tigecycline: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Children &ge; 8 years and Adolescents: Limited data available: <b>Note:</b> Use should be reserved for situations when no effective alternative therapy is available</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>General dosing, susceptible infection:</b> IV:  Dosing based on data from pharmacokinetic trials.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 8 to 11 years:  1.2 mg/kg/dose every 12 hours; maximum dose: 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years and Adolescents:  50 mg every 12 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786578\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786579\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">End-stage renal disease (ESRD) on dialysis: Poorly dialyzed; no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis, peritoneal dialysis, or continuous renal replacement therapy (eg, CVVHD). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786580\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Mild-to-moderate hepatic impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Severe hepatic impairment (Child-Pugh class C): Initial: 100 mg single dose; Maintenance: 25 mg every 12 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786583\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tygacil: 50 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786539\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786581\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Infuse over 30 to 60 minutes through dedicated line or via Y-site. If the same IV line is used for sequential infusion of several drugs, flush line with NS, D5W, or LR before and after tigecycline administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786544\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia, community-acquired bacterial:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>US labeling:</i> Treatment of community-acquired bacterial pneumonia in patients 18 years and older caused by <i>Streptococcus pneumoniae</i> (penicillin-susceptible isolates), including cases with concurrent bacteremia, <i>Haemophilus influenzae</i>, and <i>Legionella pneumophila</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Canadian labeling:</i> Treatment of mild or moderate community-acquired pneumonia in patients 18 years and older caused by <i>S. pneumoniae</i> (penicillin-susceptible isolates), <i>H. influenzae</i>, <i>Mycoplasma pneumoniae</i>, and <i>Chlamydia pneumoniae</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Intra-abdominal infections, complicated:</b> Treatment of complicated intra-abdominal infections in patients 18 years and older caused by <i>Citrobacter freundii</i>, <i>Enterobacter cloacae</i>, <i>Escherichia coli</i>, <i>Klebsiella oxytoca</i>, <i>Klebsiella pneumoniae</i>, <i>Enterococcus faecalis</i> (vancomycin-susceptible isolates), <i>Staphylococcus aureus</i> (methicillin-susceptible and methicillin-resistant isolates [US labeling] or methicillin-susceptible isolates [Canadian labeling]), <i>Streptococcus anginosus</i> group (includes <i>S. anginosus</i>, <i>Streptococcus intermedius</i>, and <i>Streptococcus constellatus</i>), <i>Bacteroides fragilis</i>, <i>Bacteroides thetaiotaomicron</i>, <i>Bacteroides uniformis</i>, <i>Bacteroides vulgatus</i>, <i>Clostridium perfringens</i>, and <i>Peptostreptococcus micros</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Skin and skin structure infections, complicated:</b> Treatment of complicated skin and skin structure infections in patients 18 years and older caused by <i>E. coli</i>, <i>E. faecalis</i> (vancomycin-susceptible isolates), <i>S. aureus</i> (methicillin-susceptible and methicillin-resistant isolates), <i>Streptococcus agalactiae</i>, <i>S. anginosus</i> group (includes <i>S. anginosus</i>, <i>S. intermedius</i>, and <i>S. constellatus</i>) [US labeling] or <i>S. anginosus</i> [Canadian labeling], <i>Streptococcus pyogenes</i>, <i>E. cloacae</i>, <i>K. pneumoniae</i>, and <i>B. fragilis</i>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786553\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Gastrointestinal: Nausea (24% to 35%), vomiting (16% to 20%), diarrhea (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Localized phlebitis (&le;3%), septic shock (&lt;2%), thrombophlebitis (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (6%), dizziness (3%), chills (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (3%), pruritus (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased amylase (3%), hyponatremia (2%), hypocalcemia (&lt;2%), hypoglycemia (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (6%), dyspepsia (2%), abnormal stools (&lt;2%), anorexia (&lt;2%), dysgeusia (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Leukorrhea (&lt;2%), vaginitis (&lt;2%), vulvovaginal candidiasis (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (5%), hypoproteinemia (5%), eosinophilia (&lt;2%), increased INR (&lt;2%), prolonged partial thromboplastin time (&lt;2%), prolonged prothrombin time (&lt;2%), thrombocytopenia (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (5%), increased serum AST (4%), increased serum alkaline phosphatase (3%), hyperbilirubinemia (2%), jaundice (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (7%), abscess (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Inflammation at injection site (&lt;2%), injection site reaction (&lt;2%), pain at injection site (&lt;2%), swelling at injection site (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased blood urea nitrogen (3%), increased serum creatinine (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pneumonia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Abnormal healing (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acute pancreatitis, allergic skin reaction, anaphylactoid reaction, anaphylaxis, <i>Clostridium difficile</i> associated diarrhea, hepatic dysfunction, hepatic failure, hypersensitivity reaction, hypoglycemia signs and symptoms (diabetic and nondiabetic patients), intrahepatic cholestasis, Stevens-Johnson syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786549\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity to tigecycline or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for tetracyclines is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in U.S. labeling): Hypersensitivity to tetracycline class of antibiotics</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786550\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylactic/hypersensitivity reactions: May cause life-threatening anaphylaxis. Due to structural similarity with tetracyclines, avoid use in patients with known hypersensitivity to tetracycline-class antibiotics  (Canadian labeling contraindicates use in patients with hypersensitivity to tetracyclines).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Antianabolic effects: May be associated with antianabolic effects observed with the tetracycline class (including increased BUN, azotemia, acidosis, and hyperphosphatemia).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatotoxicity: Abnormal liver function tests (increased total bilirubin, prothrombin time, transaminases) have been reported. Isolated cases of significant hepatic dysfunction and hepatic failure have occurred. Closely monitor for worsening hepatic function in patients who develop abnormal liver function tests during therapy. Adverse hepatic effects may occur after drug discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pancreatitis: Acute pancreatitis (including fatalities) has been reported, including patients without known risk factors; discontinue use when suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Photosensitivity: May be associated with photosensitivity due to structural similarities with tetracyclines.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pseudotumor cerebri: May be associated with pseudotumor cerebri due to structural similarities with tetracyclines.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Treatment-related mortality: <b>[US Boxed Warning]: In a meta analysis of Phase 3 and 4 clinical trials, an increase in all-cause mortality has been observed in tigecycline-treated patients versus comparator-treated patients. The cause of the mortality risk difference (0.6% [95% CI 0.1, 1.2])  has not been established. Use should be reserved for situations in which alternative treatments are not suitable.</b> In general, deaths were the result of worsening infection, complications of infection, or underlying comorbidity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment recommended in severe hepatic impairment. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Intra-abdominal infections: Avoid use as monotherapy (Canadian labeling recommends using with caution) for patients with intestinal perforation (in the small sample of available cases, sepsis/septic shock occurred more frequently than patients treated with imipenem/cilastatin comparator).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: Safety and efficacy in children and adolescents &lt;18 years of age have not been established due to increased mortality observed in trials of adult patients.  Use only if no alternative antibiotics are available. Because of effects on tooth development (yellow-gray-brown discoloration), use in patients &lt;8 years is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use:  Do not use for diabetic foot infections; non-inferiority was not demonstrated in studies. Do not use for healthcare-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP); increased mortality and decreased efficacy have been reported in HAP and VAP trials.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300141\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786559\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9458&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Warfarin: Tigecycline may increase the serum concentration of Warfarin. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786545\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786546\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Because adverse effects were observed in animals and because of the potential for permanent tooth discoloration, tigecycline is classified pregnancy category D. Tigecycline frequently causes nausea and vomiting and, therefore, may not be ideal for use in a patient with pregnancy-related nausea.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786548\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if tigecycline is found in breast milk. The manufacturer recommends caution if giving tigecycline to a nursing woman. Nondose-related effects could include modification of bowel flora.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46311140\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Monitor hepatic function periodically. Observe for signs and symptoms of anaphylaxis during administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786567\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">A glycylcycline antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, thereby, inhibiting protein synthesis. Generally considered bacteriostatic; however, bactericidal activity has been demonstrated against isolates of <i>S. pneumoniae</i> and <i>L. pneumophila</i>. Tigecycline is a derivative of minocycline (9-t-butylglycylamido minocycline), and while not classified as a tetracycline, it may share some class-associated adverse effects. Tigecycline has demonstrated activity against a variety of gram-positive and -negative bacterial pathogens including methicillin-resistant staphylococci.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F786569\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Distribution: V<sub>d</sub>: Children (8 to 11 years): 2.84 L/kg (range: 0.397 to 11.2 L/kg) (Purdy 2012); Adults: 7 to 9 L/kg; extensive tissue distribution; distributes into gallbladder, lung, and colon </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Protein binding: 71% to 89%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Metabolism: Hepatic, via glucuronidation, N-acetylation, and epimerization to several metabolites, each &lt;10% of the dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Half-life elimination: Single dose: 27 hours; following multiple doses: 42 hours;  increased by 23% in moderate hepatic impairment and 43% in severe hepatic impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Excretion: Feces (59%, primarily as unchanged drug); urine (33%, with 22% of the total dose as unchanged drug)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Clearance: Reduced by 25% in patient with moderate hepatic impairment and 55% in severe hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16324124\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Tigecycline Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $156.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Tygacil Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $187.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539958\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Capessa (TH);</li>\n      <li>Tygacil (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CY, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, HR, HU, ID, IE, IL, IN, IS, IT, JO, JP, KR, KW, LB, LT, LU, LV, MT, MX, MY, NL, NO, NZ, PE, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW, VE, VN);</li>\n      <li>Tyhatsyl (UA);</li>\n      <li>Tylin (LK);</li>\n      <li>Widebac IV (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bergallo C, Jasovich A, Teglia O, et al, &ldquo;Safety and Efficacy of Intravenous Tigecycline in Treatment of Community-Acquired Pneumonia: Results From a Double-Blind Randomized Phase 3 Comparison Study With Levofloxacin,&rdquo; <i>Diagn Microbiol Infect Dis</i>, 2009, 63(1):52-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/18990531/pubmed\" target=\"_blank\" id=\"18990531\">18990531</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Conte JE Jr, Golden JA, Kelly MG, et al, &quot;Steady-State Serum and Intrapulmonary Pharmacokinetics and Pharmacodynamics of Tigecycline,&quot; <i>Int J Antimicrob Agents</i>, 2005, 25(6):523-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/15885987/pubmed\" target=\"_blank\" id=\"15885987\">15885987</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dartois N, Castaing N, Gandjini H, et al, &ldquo;Tigecycline Versus Levofloxacin for the Treatment of Community-Acquired Pneumonia: European Experience,&rdquo; <i>J Chemother</i>, 2008, 20(Suppl 1):28-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/19036672/pubmed\" target=\"_blank\" id=\"19036672\">19036672</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fritsche TR and Jones RN, &quot;Antimicrobial Activity of Tigecycline (GAR-936) Tested Against 3498 Recent Isolates of <i>Staphylococcus aureus</i> Recovered From Nosocomial and Community-Acquired Infections,&quot; <i>Int J Antimicrob Agents</i>, 2004, 24(6):567-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/15555879/pubmed\" target=\"_blank\" id=\"15555879\">15555879</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobus NV, McDermott LA, Ruthazer R, et al, &quot;In Vitro Activities of Tigecycline Against the <i>Bacteroides fragilis</i> Group,&quot; <i>Antimicrob Agents Chemother</i>, 2004, 48(3):1034-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/14982803/pubmed\" target=\"_blank\" id=\"14982803\">14982803</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipsky BA, Berendt AR, Cornia PB, et al, &quot;2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,&quot; <i>Clin Infect Dis</i>, 2012, 54(12):e132-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/22619242/pubmed\" target=\"_blank\" id=\"22619242\">22619242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Munoz-Price LS and Weinstein RA, &ldquo;Acinetobacter Infection,&rdquo; <i>N Engl J Med</i>, 2008, 358(12):1271-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/18354105/pubmed\" target=\"_blank\" id=\"18354105\">18354105</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Muralidharan G, Micalizzi M, Speth J, et al, &quot;Pharmacokinetics of Tigecycline After Single and Multiple Doses in Healthy Subjects,&quot; <i>Antimicrob Agents Chemother</i>, 2005, 49(1):220-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/15616299/pubmed\" target=\"_blank\" id=\"15616299\">15616299</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peleg AY, Potoski BA, Rea R, et al, &ldquo;<i>Acinetobacter baumannii</i> Bloodstream Infection While Receiving Tigecycline: A Cautionary Report,&rdquo; <i>J Antimicrobic Chemother</i>, 2007, 59(1):128-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/17082201/pubmed\" target=\"_blank\" id=\"17082201\">17082201</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Purdy J, Jouve S, Yan JL, et al. Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. <i>Clinical Therapeutics</i>. 2012;34(2): 496-507.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/22249106/pubmed\" target=\"_blank\" id=\"22249106\">22249106</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rose WE and Rybak MJ, &ldquo;Tigecycline: First of a New Class of Antimicrobial Agents,&rdquo; <i>Pharmacotherapy</i>, 2006, 26(8):1099&ndash;110.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/16863487/pubmed\" target=\"_blank\" id=\"16863487\">16863487</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2010, 50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tanaseanu C, Bergallo C, Teglia O, et al, &ldquo;Integrated Results of 2 Phase 3 Studies Comparing Tigecycline and Levofloxacin in Community-Acquired Pneumonia,&rdquo; <i>Diagn Microbiol Infect Dis</i>, 2008, 61(3):329-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/18508226/pubmed\" target=\"_blank\" id=\"18508226\">18508226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tygacil (tigecycline) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tygacil (tigecycline) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zhanel GG, Homenuik K, Nichol K, et al, &quot;The Glycylcyclines: A Comparative Review With the Tetracyclines,&quot; <i>Drugs</i>, 2004, 64(1):63-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tigecycline-drug-information/abstract-text/14723559/pubmed\" target=\"_blank\" id=\"14723559\">14723559</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9458 Version 120.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F22813605\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F786537\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F9749224\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F786540\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F786577\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F22813606\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F786578\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F786579\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F786580\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F786583\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F786539\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F786581\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F786544\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F786553\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F786549\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F786550\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300141\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F786559\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F786545\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F786546\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F786548\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F46311140\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F786567\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F786569\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16324124\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539958\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9458|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tigecycline-patient-drug-information\" class=\"drug drug_patient\">Tigecycline: Patient drug information</a></li><li><a href=\"topic.htm?path=tigecycline-pediatric-drug-information\" class=\"drug drug_pediatric\">Tigecycline: Pediatric drug information</a></li></ul></div></div>","javascript":null}